This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 2008 May 21;299(19):2324-6.

doi: 10.1001/jama.299.19.jed80027. Epub 2008 Apr 28.

The future of clinical trials evaluating blood substitutes

Dean A Fergusson, Lauralyn McIntyre

PMID: 18443022
DOI: 10.1001/jama.299.19.jed80027

Editorial

The future of clinical trials evaluating blood substitutes

Dean A Fergusson et al. JAMA. 2008.

. 2008 May 21;299(19):2324-6.

doi: 10.1001/jama.299.19.jed80027. Epub 2008 Apr 28.

Authors

Dean A Fergusson, Lauralyn McIntyre

PMID: 18443022
DOI: 10.1001/jama.299.19.jed80027

No abstract available

PubMed Disclaimer

Comment in

Hemoglobin-based blood substitutes and risk of myocardial infarction and death.
Keipert PE, Olofsson C, Winslow RM. Keipert PE, et al. JAMA. 2008 Sep 17;300(11):1295-6; author reply 1298-9. doi: 10.1001/jama.300.11.1295-b. JAMA. 2008. PMID: 18799435 No abstract available.
Hemoglobin-based blood substitutes and risk of myocardial infarction and death.
Levien LJ, Hodgson RE, James MF. Levien LJ, et al. JAMA. 2008 Sep 17;300(11):1295; author reply 1298-9. doi: 10.1001/jama.300.11.1295-a. JAMA. 2008. PMID: 18799436 No abstract available.
Hemoglobin-based blood substitutes and risk of myocardial infarction and death.
Sarani B, Gracias V. Sarani B, et al. JAMA. 2008 Sep 17;300(11):1297-8; author reply 1298-9. doi: 10.1001/jama.300.11.1297-b. JAMA. 2008. PMID: 18799439 No abstract available.
Hemoglobin-based blood substitutes and risk of myocardial infarction and death.
Sauaia A, Moore EE, Banerjee A. Sauaia A, et al. JAMA. 2008 Sep 17;300(11):1297; author reply 1298-9. doi: 10.1001/jama.300.11.1297-a. JAMA. 2008. PMID: 18799440 No abstract available.

Comment on

Cell-free hemoglobin-based blood substitutes and risk of myocardial infarction and death: a meta-analysis.
Natanson C, Kern SJ, Lurie P, Banks SM, Wolfe SM. Natanson C, et al. JAMA. 2008 May 21;299(19):2304-12. doi: 10.1001/jama.299.19.jrv80007. Epub 2008 Apr 28. JAMA. 2008. PMID: 18443023 Free PMC article.

Similar articles

[Present status and future prospects in development of blood substitutes].
Sekiguchi S. Sekiguchi S. Nihon Naika Gakkai Zasshi. 1998 May 10;87(5):941-9. Nihon Naika Gakkai Zasshi. 1998. PMID: 9648449 Review. Japanese. No abstract available.
Artificial blood quickens. Several short-term substitutes approach final clinical trials.
Gibbs WW. Gibbs WW. Sci Am. 1996 Sep;275(3):44, 48. Sci Am. 1996. PMID: 8701293 No abstract available.
Hemoglobin-based blood substitutes and risk of myocardial infarction and death.
Lewis RJ, Fost N. Lewis RJ, et al. JAMA. 2008 Sep 17;300(11):1296; author reply 1298-9. doi: 10.1001/jama.300.11.1296-a. JAMA. 2008. PMID: 18799438 No abstract available.
Hemoglobin-based blood substitutes and risk of myocardial infarction and death.
Shander A, Javidroozi M, Thompson G. Shander A, et al. JAMA. 2008 Sep 17;300(11):1296-7; author reply 1298-9. doi: 10.1001/jama.300.11.1296-b. JAMA. 2008. PMID: 18799437 No abstract available.
The risks of blood transfusions and the shortage of supply leads to the quest for blood substitutes.
Nouwairi NS. Nouwairi NS. AANA J. 2004 Oct;72(5):359-64. AANA J. 2004. PMID: 15529732 Review.

See all similar articles

Cited by

Efficacy of the perfluorocarbon dodecafluoropentane as an adjunct to pre-hospital resuscitation.
Bonanno AM, Graham TL, Wilson LN, Madtson BM, Ross JD. Bonanno AM, et al. PLoS One. 2018 Nov 29;13(11):e0207197. doi: 10.1371/journal.pone.0207197. eCollection 2018. PLoS One. 2018. PMID: 30496190 Free PMC article.
Progresses in overcoming the limitations of in vitro erythropoiesis using human induced pluripotent stem cells.
Ju H, Sohn Y, Nam Y, Rim YA. Ju H, et al. Stem Cell Res Ther. 2024 May 15;15(1):142. doi: 10.1186/s13287-024-03754-9. Stem Cell Res Ther. 2024. PMID: 38750578 Free PMC article. Review.
Safety of cell therapy with mesenchymal stromal cells (SafeCell): a systematic review and meta-analysis of clinical trials.
Lalu MM, McIntyre L, Pugliese C, Fergusson D, Winston BW, Marshall JC, Granton J, Stewart DJ; Canadian Critical Care Trials Group. Lalu MM, et al. PLoS One. 2012;7(10):e47559. doi: 10.1371/journal.pone.0047559. Epub 2012 Oct 25. PLoS One. 2012. PMID: 23133515 Free PMC article.
Dodecafluoropentane emulsion decreases infarct volume in a rabbit ischemic stroke model.
Culp WC, Woods SD, Skinner RD, Brown AT, Lowery JD, Johnson JL, Unger EC, Hennings LJ, Borrelli MJ, Roberson PK. Culp WC, et al. J Vasc Interv Radiol. 2012 Jan;23(1):116-21. doi: 10.1016/j.jvir.2011.10.001. Epub 2011 Nov 12. J Vasc Interv Radiol. 2012. PMID: 22079515 Free PMC article.

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions

Substances

Actions
Actions

LinkOut - more resources

Full Text Sources
- Ovid Technologies, Inc.
- Silverchair Information Systems
Other Literature Sources
- The Lens - Patent Citations Database
Medical
- MedlinePlus Health Information